Sernova Corp At TSX Life Sciences Investor Day Transcript
I'm Dr. Philip Toleikis, President and CEO of Sernova Corp. Sernova is a publicly traded, clinical-stage, regenerative medicine therapeutics company. Type 1 diabetes is our first clinical application and we have an active Phase II clinical trial ongoing at the University of Chicago that I will be speaking about today.
In addition, we have two other programs that we have strong proof-of-concept data pre-clinically. These include hemophilia A, which is a chronic bleeding disorder in patients and also, hypothyroid disease. And this is a treatment for patients that are having their thyroid gland removed and have to be on chronic medications every day for the rest of their lives.
Our approach involves a -- three technologies that we put together in a very simple kind of approach. The first is a Cell Pouch, which is a medical device, about three-quarters the size of a business card that is placed deep under the skin and it forms an organ-like environment for therapeutic cells after a couple of weeks. We then place therapeutic cells, which then
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
